PPA
ICPT

Parametric Portfolio Associates’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Parametric Portfolio Associates’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.49M Buy
91,263
+5,395
+6% +$84.5K ﹤0.01% 2576
2021
Q4 		$1.4M Buy
85,868
+56,507
+192% +$953K ﹤0.01% 2637
2021
Q3 		$436K Sell
29,361
-3,739
-11% -$59.8K ﹤0.01% 3163
2021
Q2 		$661K Buy
33,100
+8,201
+33% +$163K ﹤0.01% 2968
2021
Q1 		$575K Sell
24,899
-761
-3% -$21.2K ﹤0.01% 3434
2020
Q4 		$634K Buy
25,660
+2,937
+13% +$97.3K ﹤0.01% 3266
2020
Q3 		$942K Sell
22,723
-5,081
-18% -$233K ﹤0.01% 2958
2020
Q2 		$1.33M Sell
27,804
-3,325
-11% -$257K ﹤0.01% 2759
2020
Q1 		$1.96M Sell
31,129
-12,026
-28% -$1.08M ﹤0.01% 2388
2019
Q4 		$5.35M Buy
43,155
+11,388
+36% +$1.02M ﹤0.01% 2018
2019
Q3 		$2.11M Sell
31,767
-4,865
-13% -$327K ﹤0.01% 2603
2019
Q2 		$2.92M Sell
36,632
-23,941
-40% -$2.14M ﹤0.01% 2399
2019
Q1 		$6.78M Sell
60,573
-274
-0.5% -$29.9K 0.01% 1736
2018
Q4 		$6.13M Buy
60,847
+2,299
+4% +$238K 0.01% 1720
2018
Q3 		$7.4M Buy
58,548
+291
+0.5% +$30.8K 0.01% 1693
2018
Q2 		$4.89M Buy
58,257
+9,198
+19% +$673K ﹤0.01% 1982
2018
Q1 		$3.02M Buy
49,059
+37,174
+313% +$2.24M ﹤0.01% 2306
2017
Q4 		$694K Buy
11,885
+6,683
+128% +$421K ﹤0.01% 3179
2017
Q3 		$302K Sell
5,202
-21,133
-80% -$2.28M ﹤0.01% 3671
2017
Q2 		$3.19M Sell
26,335
-1,672
-6% -$194K ﹤0.01% 2157
2017
Q1 		$3.17M Buy
28,007
+11,933
+74% +$1.39M ﹤0.01% 2128
2016
Q4 		$1.75M Buy
16,074
+9,104
+131% +$1.08M ﹤0.01% 2469
2016
Q3 		$1.15M Buy
6,970
+1,355
+24% +$214K ﹤0.01% 2718
2016
Q2 		$801K Buy
5,615
+1,814
+48% +$264K ﹤0.01% 2971
2016
Q1 		$488K Sell
3,801
-595
-14% -$70.3K ﹤0.01% 3345
2015
Q4 		$657K Buy
4,396
+58
+1% +$9.82K ﹤0.01% 3081
2015
Q3 		$720K Sell
4,338
-2,272
-34% -$500K ﹤0.01% 2528
2015
Q2 		$1.6M Buy
6,610
+2,111
+47% +$562K ﹤0.01% 2421
2015
Q1 		$1.27M Buy
4,499
+2,346
+109% +$508K ﹤0.01% 2605
2014
Q4 		$336K Buy
+2,153
New +$398K ﹤0.01% 3484
2014
Q3 		– Sell
-3,088
Closed -$731K – 3883
2014
Q2 		$731K Buy
+3,088
New +$814K ﹤0.01% 2958

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parametric Portfolio Associates's ICPT Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 6.3% in Q1 2022, buying an estimated $84.5K and bringing the position to 91,263 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

Parametric Portfolio Associates first reported a position in ICPT in Q2 2014 and has held it in 31 quarters since. The position peaked at $7.4M in Q3 2018. 148 funds tracked by Wall St. Rank hold ICPT as of Q1 2022.

  • Parametric Portfolio Associates held 91,263 shares of Intercept Pharmaceuticals, Inc. worth $1.49M as of Q1 2022.
  • Parametric Portfolio Associates bought 5,395 Intercept Pharmaceuticals, Inc. shares in Q1 2022, an estimated $84.5K.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2576 holding.
  • Parametric Portfolio Associates first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and has held it in 31 quarters since.
  • Parametric Portfolio Associates's Intercept Pharmaceuticals, Inc. position peaked at $7.4M in Q3 2018.
  • 148 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.